Nvidia bets on agentic AI to turbocharge biotech discovery
Nvidia made a prominent push at the Bio International Convention in San Diego, with executive Kimberly Powell outlining the company's bet on agentic AI to accelerate biotech drug discovery. The move signals a major shift in how AI infrastructure companies are positioning themselves within the life sciences ecosystem. Nvidia's agentic AI framework aims to automate and speed up complex biological research workflows.
The Atomic take
By targeting Bio International's drug-discovery crowd directly, Nvidia is moving beyond selling chips toward owning the research workflow itself, with Powell's agentic framework pitched to handle the multi-step grind of biological experimentation. The real test is whether these autonomous agents can shorten actual preclinical timelines rather than just generating more candidate molecules that still fail in the lab. Watch which pharma and longevity-focused biotechs commit to building on Nvidia's stack versus keeping their AI pipelines in-house.
Read the full story at SiliconANGLE News →Know where humanity is headed.
Five forces. One brief. Free, every Monday morning.
Get The Atomic Five